
Sign up to save your podcasts
Or


For decades, the best drug therapies for treating depression, like SSRIs, have been based on the idea that depressed brains don’t have enough of the neurotransmitter serotonin. Yet for almost as long, it’s been clear that simplistic theory is wrong. Recent research into the true causes of depression is finding clues in other neurotransmitters and the realization that the brain is much more adaptable than scientists once imagined. Treatments for depression are being reinvented by drugs like ketamine that can help regrow synapses, which can in turn restore the right brain chemistry and improve whole body health.
In this episode, John Krystal, a neuropharmacologist at the Yale School of Medicine, tells Steve Strogatz about the new findings in mental health research that are revolutionizing psychiatric medication.
By Steven Strogatz, Janna Levin and Quanta Magazine4.9
482482 ratings
For decades, the best drug therapies for treating depression, like SSRIs, have been based on the idea that depressed brains don’t have enough of the neurotransmitter serotonin. Yet for almost as long, it’s been clear that simplistic theory is wrong. Recent research into the true causes of depression is finding clues in other neurotransmitters and the realization that the brain is much more adaptable than scientists once imagined. Treatments for depression are being reinvented by drugs like ketamine that can help regrow synapses, which can in turn restore the right brain chemistry and improve whole body health.
In this episode, John Krystal, a neuropharmacologist at the Yale School of Medicine, tells Steve Strogatz about the new findings in mental health research that are revolutionizing psychiatric medication.

325 Listeners

838 Listeners

565 Listeners

540 Listeners

247 Listeners

1,071 Listeners

81 Listeners

4,181 Listeners

2,356 Listeners

448 Listeners

505 Listeners

252 Listeners

330 Listeners

26 Listeners

390 Listeners

505 Listeners